Kodiak Sciences presents a speculative setup: analyst consensus implies roughly 60% upside and technical accumulation is underway, but negative free cash flow, the absence of a competitive moat, and 26% short interest disqualify the stock at current quality levels — patience is warranted until the business demonstrates a path to self-sufficiency.
Thesis pillars
- Analyst Implied Large Upside↑Improving
- Cash Burning No Competitive Moat→Stable
- High Short Interest Binary Risk↑Improving
- +1 more pillar — see the Why tab for full reasoning
Kodiak Sciences Inc (KOD) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $81.09: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 1.55; Below-average business quality.
Kodiak Sciences is a clinical-stage biotechnology company built around its proprietary Antibody Biopolymer Conjugate (ABC) platform for retinal disease therapies, with three investigational medicines in its pipeline: tarcocimab (Zenkuda), KSI-501 and KSI-101, targeting diabetic... Read more
Sell if holding. Engine safety override at $81.09: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 1.55; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 28d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Kodiak Sciences Inc
About Kodiak Sciences Inc
Kodiak Sciences has no approved products and depends entirely on its Antibody Biopolymer Conjugate platform, which underlies three clinical-stage retinal disease candidates: tarcocimab (Zenkuda), an anti-VEGF therapy that completed four Phase 3 studies; KSI-501, an IL-6/VEGF bispecific; and KSI-101, targeting macular edema secondary to inflammation. Topline data from the ongoing Phase 3 DAYBREAK trial, covering both tarcocimab and KSI-501 in wet age-related macular degeneration, are expected in the third quarter of 2026.
Kodiak's commercial-scale manufacturing runs through Ursus, a dedicated drug-substance facility built and operated in partnership with contract manufacturer Lonza under an agreement with an initial eight-year term extendable to sixteen years; Kodiak released its first commercial-scale cGMP batch of tarcocimab in July 2023. The company retains full global rights to its product candidates rather than out-licensing them, aiming to preserve future economics and commercialization control if tarcocimab, KSI-501 or KSI-101 win approval. Tarcocimab's six completed pivotal studies produced mixed results: GLOW1, GLOW2, BEACON and DAYLIGHT met their primary endpoints, while GLEAM, GLIMMER and the earlier DAZZLE study did not, with GLEAM and GLIMMER showing an unexpected rise in cataract adverse events (19% on tarcocimab versus 9% on aflibercept) that Kodiak believes contributed to those misses.
Show full overview
Kodiak's near-term valuation hinges on a single binary event: the one-year primary endpoint readout from the Phase 3 DAYBREAK trial, expected in the third quarter of 2026, which will determine whether both tarcocimab and KSI-501 can proceed toward a BLA filing for diabetic retinopathy, retinal vein occlusion and wet AMD. The 10-K states that Kodiak's prospects are heavily dependent on successfully developing, winning approval for and commercializing tarcocimab, KSI-501 and KSI-101 — with three prior tarcocimab trials (GLEAM, GLIMMER, DAZZLE) already having missed their primary endpoints, underscoring the binary nature of the DAYBREAK outcome.
See also: Healthcare · Biotechnology
From Kodiak Sciences Inc's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-15Recent Developments — Kodiak Sciences Inc
Latest news
- NEWS HC Wainwright & Co. Maintains Buy on Kodiak Sciences, Raises Price Target to $126 — benzinga Oct 12, 2026 positive
- NEWS Top 3 Health Care Stocks That May Collapse In Q4 — benzinga Oct 5, 2026 negative
- NEWS MongoDB, Kodiak Sciences, Navitas Semiconductor, Boeing and Nvidia: Why These 5 Stocks Are on Investors' Radars Today — benzinga Sep 28, 2026 neutral
- NEWS Gold Tumbles Over 3%; MongoDB Shares Move Lower — benzinga Sep 28, 2026 negative
- NEWS Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday — benzinga Sep 28, 2026 positive
Generated 2026-10-15T11:47:13Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinetarcocimab, KSI-501 and KSI-10110-K Item 1A: 'Our prospects are heavily dependent on our ability to successfully develop, obtain regulatory approval for and successfully commercialize tarcocimab, KSI-501 and KSI-101'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $81.09: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 1.55; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $75.41. Score 5.3/10, moderate confidence.
Take-profit target: $105.85 (+30.5% upside). Prior stop was $75.41. Stop-loss: $75.41.
Concentration risk — Pipeline: tarcocimab, KSI-501 and KSI-101; Quality below floor (1.7 < 4.0).
Kodiak Sciences Inc trades at a P/E of N/A (forward -23.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
10 analysts cover KOD with a consensus score of 4.1/5. Average price target: $122.
What does Kodiak Sciences Inc do?Kodiak Sciences is a clinical-stage biotechnology company built around its proprietary Antibody Biopolymer Conjugate...
Kodiak Sciences is a clinical-stage biotechnology company built around its proprietary Antibody Biopolymer Conjugate (ABC) platform for retinal disease therapies, with three investigational medicines in its pipeline: tarcocimab (Zenkuda), KSI-501 and KSI-101, targeting diabetic retinopathy, retinal vein occlusion, wet age-related macular degeneration and macular edema. The company has no approved products and depends on topline results from its ongoing Phase 3 DAYBREAK trial, expected in the third quarter of 2026, to support planned regulatory filings for tarcocimab.